摘要
目的:厘清我国普惠型商业医疗保险对罕见病用药保障的现状与发展趋势。方法:系统收集2021-2022年全国各省份实施的普惠型商保方案及其特定药品目录,进行定性描述与定量分析。结果:2021-2022年,保障罕见病用药的普惠型商保方案数量有所增加,普惠型商业医疗保险覆盖的罕见病特药数量也有所增加;2022年,更多普惠型商业医疗保险为罕见病特药单独设置了保障水平,该水平低于一般特药保障。结论:普惠型商业医疗保险对罕见病用药的保障不断优化,但罕见病用药保障水平的提高仍需多层次保障体系中各方共同努力。
Objective:To clarify the current status and development trend of the security of drugs for rare diseases by inclusive commercial medical insurance.Method:Quantitative and qualitative methods were conducted on the inclusive commercial medical in-surance programs and specific drug lists covering various cities all over the country during 2021-2022.Results:From 2021 to 2022,the number of CSP schemes covering medicines for rare diseases increases,and the number of rare disease specialty medicines cov-ered by GSP increases.2022 sees more CSP schemes setting separate coverage levels for rare disease specialty medicines,which are lower than general specialty medicines coverage.Conclusion:Rare disease drug coverage under universal commercial insurance con-tinues to be optimized,but improving the level of rare disease drug coverage still requires the concerted efforts of all parties in the multi-level coverage system.
作者
童禧辰
尚春晓
陈文
张璐莹
Tong Xichen;Shang Chunxiao;Chen Wen(School of Public Health,Fudan University,Shanghai,200032,China;不详)
出处
《中国卫生经济》
北大核心
2023年第9期36-38,共3页
Chinese Health Economics
基金
国家社会科学基金重大项目(20ZDA072)。
关键词
普惠型商业医疗保险
罕见病
用药保障
inclusive commercial insurance
rare disease
medication assurance
